Hypophosphatemia in HBV hepatitis patients receiving adefovir

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SUN 234-256-Bone & Calcium Metabolism: Clinical Trials & Case Series
Clinical
Sunday, June 16, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SUN-256
Seonbin Hong*1, Jooyoung Han2, So Hun Kim3, Moonsuk Nam3 and Yong-Sung Kim4
1Inha University School of medicine, Incheon, South Korea, 2Inha University, Incheon, South Korea, 3Inha university, 4Inha University Hospital, Seoul City, South Korea
Adefovir dipivoxil (ADV) is an acyclic nucleoside analogue, which has been approved as the treatment for the patients with chronic hepatitis B. It is particularly efficacious in those who have   developed lamivudine resistance. It exhibits nephrotoxicity with severe hypophosphatemia when administered at a high dosage in HIV+ patients. However, it is not rare in low dose treatment like in the HBV hepatitis. We report two cases that developed osteomalacia with hypophosphatemia during the chronic hepatitis B treatment with adefovir and also reviewed 575 HBV hepatitis patients who had been received adefovir to know predicting clinical variables. 64 and 59 year male complained muscle weakness and bone pain. Laboratory findings showed hypophoatemia and elevated ALP levels. Multiple active lesions were found in bone scans. Baseline phosphorus and renal function were available in 226 patients. Hypophosphatemia was identified in 12 patients and persistent one was in 7 patients. First case was found after 2 year treatment. Age and creatinine clearance predict hypophosphatemia. Although symptomatic osteomalacia was not frequent.. Phosphate level should be measured in patient with renal insufficiency and old age.

Nothing to Disclose: SH, JH, SHK, MN, YSK

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm

<< Previous Abstract | Next Abstract